Amgen: Tepezza (teprotumumab) Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...
Medindia4h
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) ...
dvm36014h
Biopharmaceutical seeks to raise $15M to develop cancer therapy for pets
CureLab Veterinary Inc, a biopharmaceutical company that develops cancer treatments for pets, announced a Regulation D ...
These Are the Most Common Colon Cancer Symptoms in Young People
But before you assume every stomach gurgle is sinister, know that it’s not super common in younger adults: There are one to ...
Northern Arizona Jewish News15h
Gut-friendly recipes for the High Holidays
Crohn’s disease and ulcerative colitis, which are the most common types of inflammatory bowel disease (IBD), are more common ...
Why the key to preventing cancer under 50 lies in your gut
Cancer cases in the under-50s are rising, and experts believe it may be linked to their gut health. Here’s how to fix it ...